Study indicates interleukin-6-dependant pathway dysregulation as a key druggable feature of COVID-19
In a recent study on the medRxiv* preprint server, researchers identified an interleukin 6 (IL-6) dependent alternative pathway as a therapeutic strategy against coronavirus disease 2019 (COVID-19).
Priority review for ravulizumab in IgA nephropathy could establish the first C5 complement inhibitor label in this indication, addressing substantial residual progression risk despite current standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results